Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion
Record Q1 net revenues of $19.5 million, representing an 89% increase compared to the $10.3 million of net revenues generated in Q1 2023
Q1 operating income of $3.4 million, representing an 201% increase compared to the $1.1 million of operating income generated in Q1 2023
Related news for (LOVFF)
- Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates
- Cannara Biotech Inc. to Announce Fiscal Q2 2025 Financial Results on April 28, 2025
- Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
- Cannara Biotech to Present at The Ventum Canadian Cannabis Conference on March 12th, 2025
- Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025